Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more
Atea Pharmaceuticals Inc (AVIR) - Net Assets
Latest net assets as of December 2025: $275.43 Million USD
Based on the latest financial reports, Atea Pharmaceuticals Inc (AVIR) has net assets worth $275.43 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($315.22 Million) and total liabilities ($39.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $275.43 Million |
| % of Total Assets | 87.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.21% |
| 10-Year Change | N/A |
| Growth Volatility | 22.1 |
Atea Pharmaceuticals Inc - Net Assets Trend (2018–2025)
This chart illustrates how Atea Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Atea Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Atea Pharmaceuticals Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $275.43 Million | -37.24% |
| 2024-12-31 | $438.87 Million | -20.95% |
| 2023-12-31 | $555.19 Million | -13.33% |
| 2022-12-31 | $640.57 Million | -9.79% |
| 2021-12-31 | $710.08 Million | +29.62% |
| 2020-12-31 | $547.80 Million | +1205.08% |
| 2019-12-31 | $-49.57 Million | -37.08% |
| 2018-12-31 | $-36.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Atea Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48239000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $78.00K | 0.03% |
| Other Comprehensive Income | $174.00K | 0.06% |
| Other Components | $797.75 Million | 289.63% |
| Total Equity | $275.43 Million | 100.00% |
Atea Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Atea Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ShenZhen V&T Technologies Co Ltd
SHE:300484
|
$364.80 Million |
|
Jiangsu Libert Inc
SHG:605167
|
$364.86 Million |
|
American Business Bk
OTCQX:AMBZ
|
$364.88 Million |
|
Wuestenrot & Wuerttembergische AG
LSE:0GJN
|
$364.89 Million |
|
Willis Lease Finance Corporation
NASDAQ:WLFC
|
$364.73 Million |
|
Changhong Meiling Co Ltd B
SHE:200521
|
$364.69 Million |
|
PC Jeweller Limited
NSE:PCJEWELLER
|
$364.47 Million |
|
Real Brokerage Inc
NASDAQ:REAX
|
$364.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Atea Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 438,867,000 to 275,434,000, a change of -163,433,000 (-37.2%).
- Net loss of 158,349,000 reduced equity.
- Share repurchases of 25,519,000 reduced equity.
- Other comprehensive income decreased equity by 59,000.
- Other factors increased equity by 20,494,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-158.35 Million | -57.49% |
| Share Repurchases | $25.52 Million | -9.27% |
| Other Comprehensive Income | $-59.00K | -0.02% |
| Other Changes | $20.49 Million | +7.44% |
| Total Change | $- | -37.24% |
Book Value vs Market Value Analysis
This analysis compares Atea Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-3.58 | $6.13 | x |
| 2019-12-31 | $-0.60 | $6.13 | x |
| 2020-12-31 | $6.65 | $6.13 | x |
| 2021-12-31 | $8.05 | $6.13 | x |
| 2022-12-31 | $7.69 | $6.13 | x |
| 2023-12-31 | $6.66 | $6.13 | x |
| 2024-12-31 | $5.21 | $6.13 | x |
| 2025-12-31 | $3.38 | $6.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Atea Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-57.49%) is below the historical average (-15.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.45 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.50 Million |
| 2020 | -2.00% | -22.51% | 0.06x | 1.58x | $-65.73 Million |
| 2021 | 17.07% | 34.49% | 0.45x | 1.09x | $50.18 Million |
| 2022 | -18.09% | -60.31% | 0.29x | 1.04x | $-179.97 Million |
| 2023 | -24.49% | 0.00% | 0.00x | 1.07x | $-191.48 Million |
| 2024 | -38.37% | 0.00% | 0.00x | 1.06x | $-212.27 Million |
| 2025 | -57.49% | 0.00% | 0.00x | 1.14x | $-185.89 Million |
Industry Comparison
This section compares Atea Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Atea Pharmaceuticals Inc (AVIR) | $275.43 Million | 0.00% | 0.14x | $364.79 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |